176 results on '"Mitlak, Bruce"'
Search Results
2. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
3. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
4. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis
5. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption
6. Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study.
7. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
8. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
9. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
10. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial
11. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
12. The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial.
13. Femoral strength in osteoporotic women treated with teriparatide or alendronate
14. Quality of Life in Sarcopenia and Frailty
15. Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis
16. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
17. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project.
18. Selective Estrogen Receptor Modulators: A Look Ahead
19. Chapter 21 - Pharmaceutical Treatments of Osteoporosis
20. Teriparatide and Raloxifene Reduce the Risk of New Adjacent Vertebral Fractures in Postmenopausal Women with Osteoporosis: Results from Two Randomized Controlled Trials
21. Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score
22. Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair
23. ENHANCEMENT OF EXPERIMENTAL FRACTURE-HEALING BY SYSTEMIC ADMINISTRATION OF RECOMBINANT HUMAN PARATHYROID HORMONE (PTH 1–34)
24. Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis
25. Pharmacogenomics in Endocrinology
26. THE REDUCED RISK OF NEW VERTEBRAL FRACTURE PERSISTS FOR UP TO 18 MONTHS FOLLOWING TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH RECOMBINANT HUMAN PARATHYROID HORMONE (1-34).
27. Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials
28. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
29. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
30. Update in Endocrinology
31. Effects of Raloxifene in Postmenopausal Women
32. Parathyroid hormone as a therapeutic agent
33. Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
34. Treatment‐Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained.
35. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
36. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
37. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
38. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
39. Abstract #796012: Phase 1B Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density
40. Chapter 17 - Pharmaceutical Treatments of Osteoporosis
41. Abstract #184 Effect of Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
42. Abstract #531 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Type 2 Diabetes Mellitus
43. Abstract #530 Effect of Abaloparatide Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women with Osteoporosis
44. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
45. A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density.
46. List of Contributors
47. Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
48. Is Diabetes Mellitus a Heart Disease Equivalent in Women?: Results From an International Study of Postmenopausal Women in the Raloxifene Use for the Heart (RUTH) Trial.
49. Long-term raloxifene for postmenopausal osteoporosis.
50. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.